Derya Shimshek
Investigator & Head of Lab Novartis AG
Seminars
Wednesday 3rd June 2026
Activating TREM2 to Shift Microglia toward Neuroprotection in ALS
1:30 pm
- VHB937 is a novel human mAb that binds microglial TREM2, stabilizing membrane TREM2 and activating signaling
- VHB937 demonstrates neuroprotective activity across multiple models of neurodegeneration and neuroinflammation
- In healthy participants, treatment with VHB937 decreased microglial biomarker (sCSF1R) and proinflammatory biomarkers (Spp1, Ccl3)
- VHB937 is being investigated in a phase 2 study to evaluate efficacy and safety in participants with ALS in the ASTRALS study (NCT06643481)
